Compare · NBIX vs RVMD
NBIX vs RVMD
Side-by-side comparison of Neurocrine Biosciences Inc. (NBIX) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NBIX and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $43.05B, about 3.0x NBIX ($14.58B).
- Over the past year, NBIX is up 2.1% and RVMD is up 295.0% - RVMD leads by 292.9 points.
- RVMD has been more active in the news (21 items in the past 4 weeks vs 15 for NBIX).
- Both have 25 recent analyst ratings on file.
- Company
- Neurocrine Biosciences Inc.
- Revolution Medicines Inc.
- Price
- $141.26-1.55%
- $188.00-6.41%
- Market cap
- $14.58B
- $43.05B
- 1M return
- -8.94%
- -9.48%
- 1Y return
- +2.05%
- +294.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2020
- News (4w)
- 15
- 21
- Recent ratings
- 25
- 25
Neurocrine Biosciences Inc.
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Â Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest NBIX
- SEC Form 3 filed by Neurocrine Biosciences Inc.
- Guggenheim resumed coverage on Neurocrine Biosciences with a new price target
- Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
- Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update
- Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
- Chief Scientific Officer Onyia Jude was granted 3,587 shares and covered exercise/tax liability with 1,936 shares, increasing direct ownership by 8% to 22,647 units (SEC Form 4) to satisfy withholding tax
- Chief Legal Officer Lippoldt Darin was granted 4,483 shares and covered exercise/tax liability with 2,419 shares, increasing direct ownership by 4% to 56,793 units (SEC Form 4) (withholding obligation)
- Chief Medical Officer Keswani Sanjay Chandru was granted 3,914 shares and covered exercise/tax liability with 2,112 shares, increasing direct ownership by 122% to 3,281 units (SEC Form 4) to satisfy tax liability
- Director Gorman Kevin Charles was granted 14,343 shares and covered exercise/tax liability with 7,839 shares, increasing direct ownership by 1% to 517,797 units (SEC Form 4) to cover taxes
- Chief Executive Officer Gano Kyle was granted 8,117 shares and covered exercise/tax liability with 4,380 shares, increasing direct ownership by 2% to 154,728 units (SEC Form 4) (tax withholding)
Latest RVMD
- Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
- Chief Development Officer Sandler Alan B. exercised 6,000 shares at a strike of $58.84 and sold $1,275,294 worth of shares (6,309 units at $202.14) as part of a pre-agreed trading plan, decreasing direct ownership by 0.58% to 52,559 units (SEC Form 4)
- SVP & General Counsel Cislini Jeff sold $158,600 worth of shares (765 units at $207.32) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 51,776 units (SEC Form 4)
- Officer Mancini Anthony sold $743,285 worth of shares (3,708 units at $200.45) as part of a pre-agreed trading plan and exercised 3,121 shares at a strike of $33.62, decreasing direct ownership by 1% to 39,765 units (SEC Form 4)
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- Director Anderson Elizabeth M exercised 5,070 shares at a strike of $1.12 and sold $1,958,016 worth of shares (10,143 units at $193.04) as part of a pre-agreed trading plan, decreasing direct ownership by 54% to 4,333 units (SEC Form 4)
- Goldman resumed coverage on Revolution Medicines with a new price target
- Officer Mancini Anthony sold $347,402 worth of shares (1,764 units at $196.94) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,352 units (SEC Form 4)
- Chief Development Officer Sandler Alan B. sold $67,941 worth of shares (341 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 52,868 units (SEC Form 4) to satisfy withholding tax
- Officer Mancini Anthony sold $353,449 worth of shares (1,774 units at $199.24) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 42,116 units (SEC Form 4) (for tax liability)